NervGen Pharma Corp. (NGEN.V)
| Previous Close | 1.9400 |
| Open | 1.9800 |
| Bid | 1.9400 x 0 |
| Ask | 1.9700 x 0 |
| Day's Range | 1.8800 - 2.0300 |
| 52 Week Range | 1.5200 - 3.3300 |
| Volume | |
| Avg. Volume | 44,763 |
| Market Cap | 89.508M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3540 |
| Earnings Date | Nov 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.53 |
- Newsfile
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, is pleased to announce that it has entered into binding subscription agreements for a non-brokered private placement (the "Private Placement") of
- Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for a period of five years with vesting that is either time or performance based. All ...
- Newsfile
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class
